BioSpace News Archive

SELLAS Life Sciences Group, Inc. today announced that the Company has added a second, once-a-week dose cohort in its ongoing global Phase 1 clinical trial in both the United States and China with the highly selective CDK9 inhibitor GFH009 for patients suffering from advanced relapsed or refractory lymphoma and acute myeloid leukemia (AML).

iSpecimen Inc. announced today that it has added new global biospecimen suppliers to its proprietary Marketplace platform for advancing oncology and cardiovascular disease research.

Intercept Pharmaceuticals, Inc. today announced positive topline results from a new interim analysis of its ongoing pivotal Phase 3 REGENERATE trial of OCA in patients with liver fibrosis due to nonalcoholic steatohepatitis (NASH).

Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022.

Biohaven Pharmaceutical Holding Company Ltd. today announced that it has commenced enrollment in a Phase 3 clinical trial assessing the efficacy and safety of taldefgrobep alfa in Spinal Muscle Atrophy (SMA).

Trevi Therapeutics, Inc. today announced that senior management will be attending The Twelfth London International Cough Symposium.

FDA indicates the Company may proceed with the Phase 3 clinical study of buntanetap for the treatment of Parkinson’s disease.

Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that it completed a private placement through the issuance of senior secured convertible notes .

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron.

Fusion Pharmaceuticals Inc. announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 37,200 shares of its common stock to one employee outside Fusion’s 2020 Stock Option and Incentive Plan.